Fang Shen

Fang Shen, PhD, has more than 12 years of industry experience in drug discovery and translational research. Before joining Immunome, he was Associate Scientific Director at Janssen R&D, where he led a cross-coast research team to develop novel therapeutics to treat autoimmune diseases and cancer. As a project lead, he has successfully advanced multiple small molecule and biologics projects from early discovery stage to clinical development, including JNJ-61178104, an anti-TNF/IL-17 bispecific Duobody. Prior to Janssen R&D, he had a successful career in the Immunology Department at Genentech, where he contributed to non-clinical pharmacology work on BTK inhibitors and PI3K inhibitors. Fang earned his PhD in Immunological Pharmacology at Peking Union Medical College & Chinese Academy of Medical Sciences in China. He then performed post-doctoral work at Dr. Sarah Gaffen’s lab in the University of Buffalo and was one of the key contributors deciphering IL-17 function and IL-17 receptor signal transduction.